|
|
Thailand Pharmaceuticals and Healthcare Report Q3 2008Published by: Business Monitor International Published: Sep. 15, 2008 - 69 Pages Table of Contents
AbstractContrary to our statements last quarter, it now appears that Thailand is once again pursuing compulsorylicenses on patented drugs, which will limit investment by multinationals, due to decreased sales. Thegovernment bowed to pressure from patient groups and consumer organisations. International tradesanctions are now a distinct possibility in BMI’s opinion. Accordingly, we will closely monitor forecastsfor Thailand’s US$3.5bn pharmaceutical market.Demonstrating the emergence of chronic diseases in the Asian country, it was announced in July 2008that community healthcare centres will be opened around Bangkok to help elderly people suffering fromillnesses that require regular treatment, such as dementia, diabetes and hypertension. The Thai subsidiary of Swiss drugmaker Novartis recorded 2007 sales of US$106mn, which was ahealthy 20% increase on the previous year. However, due to a weakening economy and politicaluncertainty, the company expects to see only 15% growth in 2008. Thailand's US$700mn medical device market will receive a boost if an experimental nevirapine kit ismanufactured in the country. The diagnostic is under development in Japan and will be able to warn aHIV/AIDS patient if they are allergic to the antiretroviral. Because the product has been designed for thelocal highly active antiretroviral therapy (HAART) cocktail, sales in Thailand are likely to be significant.However, BMI believes the bulk of revenue will come from other developing countries, many of whichare increasingly seeing the benefit of reducing the burden of HIV/AIDS through widespread diagnosisand treatment. In an effort to improve productivity and ultimately benefit patients, Thailand's Public Health Minister,Chaiya Sasomsab, announced that he wanted to appoint a representative from the commercialpharmaceutical industry to the board of the Government Pharmaceutical Organisation (GPO). He firstdisclosed his plan at the annual conference of the Pharmaceutical Association of Thailand in late April2008, when he also expressed concern over the quality of the drug production process at the stateenterprise. However, health officials and patient groups rejected the nomination of Teera Chakajnarodom,the President of PReMA, to the 15-member board. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||